A prospective, randomised, double-blinded, placebo-controlled study investigating the safety and tolerability of STA363 in patients with radiculopathy caused by lumbar disc herniation
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Lactic acid (Primary)
- Indications Intervertebral disc displacement
- Focus Adverse reactions
- Sponsors Stayble Therapeutics
- 03 Oct 2024 Status changed from recruiting to completed.
- 09 May 2023 According to a Stayble Therapeutics media release, first patient is planned to be treated in Q3 2023.
- 14 Apr 2023 Status changed from planning to recruiting.